Saturday 17 October 2026
Export LNTH’s income statement to Excel — free account
Lantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024. In the quarter to June 2026, revenue grew 2.68%, EPS was flat, free cash flow grew 13.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
99.70
0.29
−0.29%
Follow LNTH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
26.35 | 18.02 | 19.35 | 20.93 |
+8 more quarters Free account |
P/S ratio |
4.64 | 3.18 | 2.91 | 2.26 | |
P/FCF ratio |
18.40 | 12.85 | 12.69 | 8.14 | |
P/Operating CF |
78.40 | 39.24 | 49.81 | 32.75 | |
P/B ratio |
5.51 | 4.05 | 4.12 | 3.08 | |
Price to Tangible BV |
18.85 | 18.40 | 35.23 | 24.70 | |
EV/Sales |
4.63 | 3.22 | 3.05 | 2.38 | |
EV/EBITDA |
18.23 | 13.33 | 12.20 | 8.73 | |
EV/Operating CF |
17.46 | 12.22 | 12.05 | 7.94 | |
EV/FCF |
18.35 | 13.04 | 13.28 | 8.58 | |
Quick Ratio |
2.82 | 2.57 | 2.20 | 2.21 | |
Current Ratio |
3.06 | 2.83 | 2.70 | 2.67 | |
Net Debt/EBITDA |
(0.18) | 0.68 | 2.08 | 2.87 | |
Debt/Assets |
23.65% | 24.31% | 25.56% | 24.99% | |
Debt/Equity |
0.44 | 0.47 | 0.52 | 0.51 | |
Asset Turnover |
0.69 | 0.70 | 0.73 | 0.71 | |
Operating CF/Net income |
1.23 | 1.06 | 1.67 | 3.79 | |
Capex/Depreciation |
(0.10) | 0.07 | (0.37) | (0.49) | |
Interest Coverage |
20.39 | 16.72 | 15.20 | 8.81 | |
Research and Development Expense of Revenue |
9.84% | 10.44% | 11.67% | 12.51% | |
Selling, General and Administrative Expense of Revenue |
26.65% | 29.21% | 28.57% | 34.04% | |
Intangible Assets out of Total Assets |
0.38 | 0.40 | 0.43 | 0.43 | |
Share Based Compensation of Revenue |
5.15% | 4.25% | 4.31% | 6.38% | |
Graham Net Nets |
(0.01) | (0.04) | (0.05) | (0.07) | |
Graham Number |
43.67 | 42.12 | 35.35 | 30.29 | |
Earnings Yield |
3.79% | 5.55% | 5.17% | 4.78% | |
Free Cash Flow Yield |
5.43% | 7.78% | 7.88% | 12.29% | |
Revenue per Share |
5.96 | 5.83 | 6.03 | 5.71 | |
Operating CF per Share |
1.42 | 1.93 | 1.34 | 1.57 | |
Capex per Share |
(0.04) | 0.03 | (0.13) | (0.16) | |
Free Cash Flow per Share |
1.38 | 1.96 | 1.21 | 1.41 | |
Cash per Share |
9.11 | 7.70 | 5.32 | 5.68 | |
Shareholders Equity per Share |
20.13 | 18.73 | 16.15 | 16.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.13 | 18.73 | 16.15 | 16.65 | |
Free Cash Flow |
89.87 | 126.90 | 81.39 | 94.67 | |
Working Capital |
691.38 | 609.12 | 566.55 | 578.25 | |
Capital Expenditures |
(2.33) | 1.77 | (8.79) | (10.62) | |
Net Current Asset Value |
(75.82) | (192.01) | (237.64) | (232.10) | |
EV/EBIT |
23.84 | 17.17 | 15.13 | 10.46 | |
Capex to Sales |
0.01 | 0.00 | 0.02 | 0.03 | |
Price to Operating Income |
23.91 | 16.93 | 14.45 | 9.92 | |
| Other line items | |||||
Average Receivables |
345.32 | 352.95 | 351.73 | 356.29 | |
Average Payables |
44.50 | 45.37 | 38.73 | 55.61 | |
Average Inventory |
59.85 | 65.23 | 66.35 | 66.44 | |
Average Assets |
2,265.37 | 2,200.91 | 2,103.87 | 2,163.02 | |
Average Common Equity |
1,239.28 | 1,188.24 | 1,088.90 | 1,149.46 |
Columns are period end dates